The following document contains Lutronic’s proprietary information and is not intended to be used in any other manner other than expressly written. All business and financial data contained herein are in compliance with Korean IFRS.

Any forecast within is not individually confirmed. These are forward-looking statements that relate to the Company’s estimated business and financial performance, with expressions using ‘ forecast’, ‘assessment’, ‘plan’, or ‘expectation’(‘E’). Forward-looking information and/or any interpretation may be affected by business environments and thus includes inherent differences that may vary from the final results.

In addition, all forward-looking information is based on current market condition and the Company’s direction at present, and is subject to changes without further notice, according to changes in business environment or realignment of strategy.

The Company, its affiliates, advisors or representatives shall not be held responsible for any damages from use of information herein, including gross negligence or otherwise.

This material cannot be used as evidence for responsibilities relating to the result of investment performance of the investor.

2

LUTRONIC CORP.

3

Global Medical Laser Devices

Financial Overview Competitive Assets

• Top aesthetic laser company in

Asia

• 3-4% of global market share

• KOSDAQ listed in 2006

• Involved in Aesthetics, Spinal

Surgery, and Ophthalmology

• 264 patents / Global Regulatory

Approvals

• International network of KOLs a

nd partners in 60 countries

• World’s first laser for treating

the retina without damaging

photoreceptors

• Market capitalization of KRW

261B (USD 240M) as of

November 2017

• FY2016 revenue of about KRW

81B (USD 71M) with 70% of rev

enue from Global Sales

EVOLVING BUSINESS

Aesthetic Smart Surgery Ophthalmology

Global market : $3 B (2017),

CAGR 14%

3~4% Global MS

Continual Expansion of New

Products

Dermatology, Plastic surgery

Global market : $10 B + α (2015)

DME, CSC : MFDS, CE approval

CSME: FDA clearance

World’s first laser for treating retina

with no damage to photoreceptors.

Korean market : $300 M (2013)

Approved by MFDS (2014)

Recurring Business

Neurosurgery + other (disc pain)

4

Source: Medical Insight, Inc. 2013

5

212.9 302.4 345.2 426 502.4 588.6 206.8 158.9

176.8 224.8

218.5 256

0.0

200.0

400.0

600.0

800.0

1000.0

2011 2012 2013 2014 2015 2016

Domestic

Global

Revenue Operating Income

REVENUE TREND(CONSOLIDATED)

(Unit: KRW 100 millions) (Unit: KRW 100 millions)

Quarter Performance(5 year)

0.4 10.6

27.9

52.7 66.7

2012 2013 2014 2015 2016

0.1%

2.0%

4.3%

7.3% 7.9%

-50

0

50

100

150

200

250

1Q12 2Q12 3Q12 4Q12 1Q13 2Q13 3Q13 4Q13 1Q14 2Q14 3Q14 4Q14 1Q15 2Q15 3Q15 4Q15 1Q16 2Q16 3Q16 4Q16 1Q17 2Q17 3Q17

(KRW 100 millions) Revenue Operating Income

2017 3Q(CONSOLIDATED)

22,515 20,745

-1,448 -1052

-6.43

-5.07

-8.00

-6.00

-4.00

-2.00

0.00

-5,000

0

5,000

10,000

15,000

20,000

25,000

2017 Q2 2017 Q3

Revenue O. Income O.I. % 3Q ‘17 2Q ‘17 3Q ‘16 YoY QoQ

Revenue 20,745 22,515 18,801 10.34% -7.86%

COGS 10,479 11,401 7,662 36.77% -8.09%

Gross Profit 10,266 11,114 11,139 -7.84% -7.63%

SG&A 11,318 12,562 10,074 12.35% -9.90%

Operating Income -1,052 -1,448 1,065 Turned

Negative 27.35%

EBIT -1,324 -920 55 Turned

Negative -43.91%

Income Tax 455 578 -312 245.83% -21.28%

Net Income -1,779 -1,498 367 Turned

Negative -18.76%

(KRW millions, %)

6

18,801 20,745

1,065

-1052

5.66

-5.07

-6.00

-4.00

-2.00

0.00

2.00

4.00

6.00

8.00

-5,000

0

5,000

10,000

15,000

20,000

25,000

2016 Q3 2017 Q3

Revenue O. Income O.I. %

(KRW millions)

2017 3Q(NON-CONSOLIDATED)

21,212 19,924

1,623 1,526

7.65

7.66

7.65

7.65

7.66

7.66

0

5,000

10,000

15,000

20,000

25,000

2017 Q2 2017 Q3

Revenue O. Income O.I. % 3Q ‘17 2Q ‘17 3Q ‘16 YoY QoQ

Revenue 19,924 21,212 19,161 3.98% -6.07%

COGS 10,715 11,414 8,592 24.71% -6.12%

Gross Profit 9,209 9,798 10,569 -12.87% -6.01%

SG&A 7,683 8,175 6,715 14.42% -6.02%

Operating Income 1,526 1,623 3,854 -60.4% -5.98%

EBIT 1,373 1,854 2,908 -52.79% -25.94%

Income Tax 344 366 0 - -6.01%

Net Income 1,029 1,488 2,908 -64.61% -30.85%

7

19,161 19,924

3,854

1,526

20.11

7.66

0.00

5.00

10.00

15.00

20.00

25.00

0

5,000

10,000

15,000

20,000

25,000

2016 Q3 2017 Q3

Revenue O. Income O.I. %

(KRW millions)

(KRW millions, %)

AESTHETIC – MARKET

Source: Medical Insight, 2016 Energy-Based Device, Body Shaping & Skin Tightening Device

2,075

2,387 2,580

2,791 3,003

3,242

2015 2016 2017 2018 2019 2020

Source: Companies *Listed companies

8

Global Aesthetic Market Revenue of Global Players in 2016

(Unit: USD millions) (Unit: USD millions)

$433.5

$354

$298

$118

$71

GLOBAL AESTHETIC DEVICE MARKET

9

Source: Medical Insight, 2016 Energy-Based Device, Body Shaping & Skin Tightening Device

(Unit: USD millions)

998 1,162 1,236 1,323 1,411 1,516

479

540 593

648 705

768

426

486

533

582

629

678

172

199

218

238

258

280

0

500

1,000

1,500

2,000

2,500

3,000

3,500

2015 2016 2017 2018 2019 2020

Latin America

Asia

Europe

North America

2,075

2,387

2,580

2,791

3,003

3,242

MULTIPLE ENERGY SOURCES ENSURE OPTIMAL TREATMENT

10

MULTIPLE ENERGY SOURCES ENSURE OPTIMAL TREATMENT

11

PRODUCT

12

AESTHETIC CLINICAL RESEARCH AND GLOBAL KOL

230 + ACADEMIC PUBLICATIONS / 400+ CLINICAL STUDIES PUBLISHED IN PEER-REVIEWED JOURNALS

13

GLOBAL CLINICAL RESEARCH

GLOBAL NETWORK OF KEY OPINION LEADERS (KOL)

SMART SURGERY – MARKET (KOR)

Source: LUTRONIC

0

2000

4000

6000

8000

10000

12000

2013 2015 2017

14

Disk Pain Surgery Market (non-insurance) Macro Trends Driving Growing Demand

Trans-foraminal Epiduroscopic Laser Annuloplasty (TELA) TELA is a minimally invasive procedure technique for the management of pain caused by various spinal disorders, wherein physicians utilize a specialized epidural scope called the NeedleView CH, which is the only one of its kind worldwide.

Source: LUTRONIC

(Unit: KRW 100 millions)

PRODUCT

Lutronic became 51% shareholder in

Oct. 2013

15

Key Patents

• Apparatus for Optical Surgery and Method for

Controlling Same

• Laserview Transforminal Laser Approach

• Laser Surgical Instrument for Spine Surgery and

Method Thereof

Laser Micro-Epiduroscopy

NeedleView CH All in one Delivery system

AMD(Age-related Macular Degeneration)

DME(Diabetic Macular Edema)

CSC(Central Serous Chorioretinopathy)

16

Ultimate Goal Preventive Medicine

Approval in CE, MFDS (KFDA) / Clearance FDA (for CSME) No-Alternative Therapy

Approval in CE, MFDS (KFDA) / Clearance FDA (for CSME) Targeting: Anti-VEGF Non-responder + Anti-VEGF Combination

PLATFORM TECHNOLOGY FOR THE RETINA TREATMENT

MECHANISM OF THERAPY

Retinal Pigment Epithelium Regeneration

17

Laser

Non-Laser

Source: Asian Retina Clinical Cases, Hakyoung KIM, Hyeong Gon Yu, The Korean Retina Society. & Lutronic R&D Center

Retina layer < 300µm >

RPE layer < 5µm >

Iris

Pupil

Cornea

Lens

Retina

Optic Nerve

Blind Spot

Ciliary

VISION AND RETINA

Retina

• A thin layer of tissue lining the inner surface of the eye

• Light striking the retina is changed to an electrical signal and transmitted to the brain

18

Object

Eye

Brain (Visual Center)

Source: Health Chosun, 2012

MACULA

19

• Located in the center of the retina with caved-in and oval shape for greater light reception

• Highest concentration of Photoreceptors with no blood vessels, for central and high resolution vision

Source: NIH

MACULA

20

• Macula consists of multiple layers – Photoreceptors, Retinal Pigment Epithelial(RPE) cells, Bruch’s Membrane, and Choroid

• RPE nourishes Photoreceptors by supplying nutrients from Choroid and transporting extracellular material out through Bruch’s membrane

Photoreceptors

Retinal Pigment Epithelial Cells

Bruch’s Membrane

Choroid

Source: LUTRONIC, NIH

CENTRAL SEROUS CHORIORETINOPATHY (CSC)

21

• Leakage of fluid accumulates under the central macula, resulting in blurred or distorted vision which may progressively decline with each recurrence

• The cause is not known and believed to be exacerbated by stress

• The overall incidence is approximately 6 per 100,000 population, mostly among professional male in age of 41 to 46

• No conventional standard of care exists without causing damage, due to the occurrence in the central macula area

Source: NIH

INCIDENCE OF CSC

22

GLOBAL PATIENT 6 PER 100,000

70%

30%

Acute Chronic

USA

10%

KOREA

2%

MAJOR

EU

5%

MAJOR

ASIA

83%

Source: Incidence of CSC, Journal Ophthalmology 2008 World Bank, CIA FactBook

CLINICAL TRIAL - CSC

• Location: Germany

• No. of Patients: 14 experimental / 16 controlled

• Period: 3 months

• Result: Reduction in subretinal fluid

Stable or improved vision

Source: Klatt C, Saeger M, Oppermann T et al. Selective retina therapy for acute central serous chorioretinopathy. Br J Ophthalmol. 2011;95:83-88

0

50

100

150

200

250

300

350

400

450

BASE 1 MONTH 3 MONTHS

EXPERIMENTAL

CONTROLLED

Feb. 2014 MFDS Approval

May 2015 EU CE Approval

Oct. 2016 US FDA Clearance (CSME)

23

Reduction in Subretinal Fluid

CSC SIGNAL STUDY (KOR.)

-46-year-old female (Right eye)

Source: Seungbum Kang, Young Gun Park, Jae Ryun Kim, Eric Seifert, Dirk Theisen-Kunde, Ralf Brinkmann, and Young Jung Roh, Selective Retina Therapy in Patients with Chronic Central Serous Chorioretinopathy: A pilot study, MEDICINE

24

• Location: Korea

• No. of Patients: 12

• Period: 6 months

• Result: Reduction in subretinal fluid / Stable or

improved vision / Enhancements of retinal

sensitivity / no scotoma

CASE 7.

DIABETIC MACULAR EDEMA

Source: The Korean Retina Society. RETINA. 2011

25

Source: NIH

• As diabetes slows the metabolism, retinal vessels are unable to deliver enough nutrients, which induces neovascularization and fluid leakage, which causes macular edema

PREVALENCE OF DME

Rest of World

29%

China

20% Latin America

12%

Western

Europe

11%

United States

10%

India

9%

Other

Wealthy

Nations

6%

Japan

3%

26

85.4

24.0

19.3

Early DR DME PDR

Source: Market scope 2015

Diabetic eye disease classification

Estimated global DME population is 105 million

First target is 24million patients at a later stage of DME

(Unit: millions)

CLINICAL TRIAL – DME

Source: Roider J, Klatt C, Brinkmann R et al. Selective retina therapy (SRT) for clinical significant diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2010;248:1263-1272

Jul. 2013 MFDS Approval

Nov. 2013 EU CE Approval

Oct. 2016 US FDA Clearance (CSME)

27

• Location: Germany

• No. of patients: 39

• Period: 6 months

• Result:

Stable or improved vision

Change in thickness of fovea

DME CLINICAL TRIAL (KOR.)

Source: Young Gun Park, Jae Ryun Kim, Seungbum Kang, Eric Seifert, Dirk Theisen-Kunde, Ralf Brinkmann,Young-Jung Roh / Safety and Efficacy of Selective Retina Therapy (SRT) for the Treatment of Diabetic Macular Edema in Korean Patients. / Graefes Arch Clin Exp Ophthalmol DOI 10.1007/s00417-015-3262-1

28

• Location: Korea

• No. of Patients: 21 (23 eyes)

• Period: 6 months

• Result: Stable or improved vision / Change in thickness of fovea / Improved retinal sensitivity / Demonstrated

clinically significant effect and safety on Korean patients

11.8(2)

17.6(3)

41.2(7)

29.4(5)

0

10

20

30

40

50

≥1-line

deterioration

Stable (<1-

line change)

≥1-line to

<2-line

improvement

≥2-line

improvement

(%)

11.8(2)

29.4(5)

23.5(4)

35.3(6)

0

10

20

30

40

MMT increased

≥5%

compared to

baseline

MMT stationary

(<5% change

compared to

baseline)

MMT decreased

≥5% to <10%

compared to

baseline

improvement

MMT decreased

≥10%

compared to

baseline

Dis

trib

uti

on

of

chan

ges

in M

MT (

%)

Vision Improvement Retinal Thickness Improvement

AGE-RELATED MACULAR DEGENERATION (AMD)

29

As aging progresses, the ability of the RPE cells to nourish the photoreceptors diminishes

• Dry AMD: Degraded RPE cells fail to transport extracellular material which then begins to build up (Drusen) in between Bruch’s membrane and the RPE

- Drusen interfere with the supply of nutrients to the photoreceptors which could lead to vision loss

- Approximately 90% of AMD patients suffer from Dry AMD

• Wet AMD: As Dry AMD advances, new blood vessels grow (neovascularization) and penetrate Bruch’s membrane and RPE cells in order to supply nutrients to the photoreceptors

- The new and immature blood vessels are weak and prone to bleeding and leakage, resulting in blood and protein leakages,

thus damaging the photoreceptors and fueling rapid vision loss

- Approximately 10% of AMD patients suffer from Wet AMD

Dry AMD Wet AMD Vision Loss by AMD 90% 10%

Source: LUTRONIC

Drusen

PREVALENCE OF AMD

30

84.2%

6.4% 7.8%

1.6%

Early AMD GA only Neovascular

only

Neovascular &

GA

Rest of World

31%

Western

Europe

15% China

13%

India

13%

Latin America

11%

United States

9%

Other Wealthy

Nations

5%

Japan

3%

Source: Market scope 2015

NO Current Treatment

Disease Classification

Estimated global Dry AMD population is 90% of 138 million

(Unit: millions)

DRY-AMD BASIC CLINICAL STUDY

Source : Johann Roider, Ralf Brinkmann, Christopher Wirbelauer, Horst Laqua, Reginald Birngruber/ Subthreshold (retinal pigment epithelium) photocoagulation in macular diseases: a pilot study / Br J Ophthalmol 2000;84:40–47

Fundus image before (A) and 6 months after subthreshold RPE treatment (B).A change in the drusen pattern is notable (arrows).

• Location: Germany

• No. of Patients: 10

• Period : 5 Patients - 6 months(Follow-up)

5 Patients – 1 year (Follow-up)

• Result : 7 Patients - drusen decreased

(3 Patients - drusen disappeared)

31

CSC DME AMD

Target: 6 per 100,000 (30%)

Existing treatments: None

Target: 90% of 138 M patients

Existing treatments

wet-AMD: anti-VEGF*,

PC, etc.

dry-AMD: None

Target: 24 M patients

Existing treatments

anti-VEGF*

PC(Photo-coagulation

Laser)

32

*Anti-VEGF Global Market (2015): Approximately 10B (USD) Indication: DME + wet-AMD Lucentis (Norvatis) + Eylea (Bayer) + Avastin (Roche)

PLATFORM TECHNOLOGY FOR THE RETINA TREATMENT

Photocoagulation Laser Anti-VEGF Injection Steroid Injection Surgery (i.e. Vitrectomy)

Ranibizumab 2,140 USD

Aflibercept 2,040 USD

Post-PC treatment

scars

• PC treatment causes secondary thermal damage to the surrounding tissues and leaves permanent scars.

• If the macula is treated with a PC laser, permanent loss of visual acuity will occur.

Bevacizumab 240 USD

(OFF-LABEL)

33

SOURCE: MARKETSCOPE 2015

Pan-Retinal Photocoagulation Sample Only for DME, wet-AMD

CURRENT TREATMENTS FOR RETINAL DISEASE

PC VS. R:GEN

RPE

RPE

Source 1 Source 2 (X500) (X200)

R:GEN Conventional Photocoagulation

34

Selectively damages RPE cells to repair or regenerate

Source1: Roider, Brinkmann. Selective retinal pigment epithelium laser treatment theoretinal and clinical aspects. Laser in Ophthalmology – Basic, Diagnostic and Surgical Aspects, pp. 119-129 Source2: Lutronic

•Vision loss (scotoma, scar)

•Fovea treatment is impossible

•White burn

•Irradiation selectively damages only the RPE

•Fovea irradiation possible

•Automatic dosimetry for added safety

ANTI-VEGF / DME

Source: Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema, The new england journal of medicine, John A. Wells, M.D., Palmetto Retina Center, West Columbia, 2015

• Location: 89 sites

• No. of Patients: 660 (mean age, 61±10 years)

• Period: 1 year (Follow-up)

• Patients of Non-Respondent:

Eylea 37% / Avastin 56% / Lucentis 46%

OPHTHALMOLOGY (MACULAR TREATMENT) – MARKET

Source: Market Scope (Dec. 2013)

36

*OFF-LABEL

6213 5984 6146 6745 7015 6944 6876

2010 2011 2012 2013 2014 2015 2016

AVASTIN

Source: Annual reports, IR data

Global Photocoagulation Laser Market Anti-VEGF Market

(Unit: USD millions)

2935 3772 3977 4205 4301 3639 2948

25 838

1881 2775

4089 5200

2010 2011 2012 2013 2014 2015 2016

EYLEA

LUCENTIS

3,797 4,815

7,076 6,086

7,728 8,148

PLATFORM TECHNOLOGY FOR THE RETINA TREATMENT

37

Microsecond Pulse Laser 527nm/ 1.7µs

Auto-control technology Laser Ramp-up and RTF Technology Pulses: 100hz / 1.7µs

Real-Time Feedback Check RPE Cells with LIGHT and SOUND in 1 µs (1 x 10-6 sec) Dual Dosimetry Sensors: Optoacoustic + Reflectometry

World’s first laser for treating the retina without damaging photoreceptors. (70 Patents)

HOW IT WORKS

RPE Layer

38

RPE Layer

Source : M. A. MAINSTER, Retinal-Temperature Increases Produced by Intense Light Sources JOURNAL OF THE OPTICAL SOCIETY OF AMERICA, VOL. 60, NO. 2

RETINA RPE CHOROID

0.1 sec

10 msec

1 msec

100µsec

10µsec

1µsec

40µm 20µm 0 40µm 20µm

R:GEN

39

R:GEN CORE TECHNOLOGY – MICROSECOND PULSE LASER

40

R:GEN CORE TECHNOLOGY – REAL-TIME FEEDBACK Auto-control technology (safety)

Check RPE Cells with LIGHT and SOUND in 1 µs (1 x 10-6 sec)

Source: LUTRONIC

(Disposable) Optoacoustic

Reflectometry

R:GEN R:GEN

Laser Ramp-up and RTF Technology

R:GEN - AIMING “MAXIMUM PROFITABILITY”

*U.S MARKET

PC ANTI-VEGF R:GEN Therapy

Social Cost $700~900 $1,800 (Average) $2,000 +

Clinic Net $700~900

(- Depreciation Cost) $300 $1,000 +

Total Cost $1,400 (Twice a year) $14,000 (Seven a year) $6,000 (Three a year)

Comparison

• Side effects (Partial

Blindness)

• Only slows down

symptoms

• Direct injection to the eye

• Develops tolerance

• Only slows down symptoms

(vision loss after a time period)

• Secured both safety and efficacy

• Immediate daily life after therapy

• Potential treatment of the cause

41

Recurring Business Model (Disposable)

1. No/Less up-front investment 2. High added-value for doctors 3. Safe, Effective + Valuable

AGING POPULATION STATISTICS

Source: future population projection: Age type group estimated future population, Korean Statistical Information Service. 2012

0

5

10

15

20

25

0

10,000

20,000

30,000

40,000

50,000

60,000

2000 2005 2010 2015 2020 2025

TOTAL POPULATION OVER 65 RATIO (%)

As Population Ages, So Does Patient Base

Source: The Korean retina Society, 2012

Diabetic

Retinopathy,

23.20%

Age-related

Macular

Degeneration

, 21.40% Detachment

of the retina,

14.70% Retinal Vein

Occlusion,

7.30%

Malignant

Myopia,

6.20%

Injury, 6.10%

ect, 21.10%

42

Aging population & rate of people 65 or above Aging population - Eye diseases percentages

(1 thou.)

INVESTMENT HIGHLIGHT

20% of Revenue into R&D

246 domestic and global patents

Innovative products

Attained

On-going

Future expansion

Continue to improve

profitability

New

Scalable

Markets

Clearances

Recurring

Business

Model

43

APPENDIX

45

COMPANY OVERVIEW

COMPANY OVERVIEW

Name Lutronic Corp.

CEO Haelyung Hwang

Date of Incorporation

July 8, 1997

Date Listed on KOSDAQ

July 4, 2006

Capital KRW 6,400 millions (Dec. 31, 2016)

Main Business

Laser and Energy-based Device Developer & Manufacture

Headquarters 219, Sowon-ro, Deogyang-gu, Goyang-si, Gyeonggi-do, Korea

Website www.lutronic.com

Employees 290 (in Head Office only), total 360

Work

Experience

The Korean Society of Medical & Biological Engineering Vice Chair

Ministry of Health and Welfare Health Technology Policy Deliberative Committee

Commissioner of high-tech medical complex, an affiliated organization of prime minister's office

Advanced Technology Center Association Director

KOSDAQ Association – Vice Chair

Ministry of Trade, Industry and Energy Internal assessment committee

Laser Systems, Inc . Vice Chair for Asia Marketing

Academic Background

Yale University (Economics, Electronic Engineering as minor)

Award Winning Career

Dec. 2013 Korea Venture Show ‘Industry Award ‘

Dec. 2010 Minister of Knowledge Economy Award (Global IT-CEO award)

Nov. 2007 Presidential Merit Award venture Industry Promotion

CEO: HAELYUNG HWANG

46

LUTRONIC CENTER

47

BOARD MEMBERS

Name BoD Profile

Charles Cholsoo Lho Outside Director

Chairman & CEO, Amicus Group

Director , Center for Global Cooperation, Samsung Economic Research Institute

Economic Research Asst, World Trade Organization

Jung Woo LEE Auditor on Board

Advisor My Assets Asset Management

Vice President Korea Securities Dealers Association

President and CEO, the Herald Korea

CEO Dongseo Securities / Coryo Securities

Haelyung HWANG CEO/Director Refer to the previous page.

KH Dominic LEE CFO/Director

Altacap: Partner - Corporate Finance

MCM, American Tape: CFO

Samsung Elec.: Marketing and Product Management

CURRENT CAPITALIZATION TABLE

CEO

FOREIGN

INSTITUTIONAL

OTHERS

Stockholder Number Rate

CEO 2,734,049 24.41%

Foreign 615,410 5.49%

Institutional 1,164,805 10.4%

Others 6,332,271 59.7%

Total 10,846,535 100.00%

Dec. 31, 2016

24.41%

5.49%

10.4%

59.7%

※ The total is based on stocks with voting rights (1,701,067 shares of convertible preferred stock are not included.)

FINANCIAL HIGHLIGHTS - STOCK PERFORMANCE

49

November 2017

Current(20 day Avg.) 11,984 KRW 52wk H/L 18,051 KRW / 10,000 KRW Market Cap $240M

Price Earning Ratio (5Y)

-500.00

0.00

500.00

1,000.00

1,500.00

2,000.00 Lutronic Healthcare KOSDAQ

FINANCIAL STATEMENTS (K-IFRS, IN KRW 0.1B, CONSOLIDATED)

SUBJECT 2014 2015 2016

Ⅰ. Current assets 324.7 561.0 1,150.0

Ⅱ. Noncurrent assets 480.0 733.9 767.1

Intangible assets 231.9 300.3 331.5

Total assets 804.7 1,294.9 1,917.1

Ⅰ. Current Liabilities 325.8 370.4 397.2

Ⅱ. Noncurrent Liabilities 153.6 176.0 165.5

total Liabilities 479.4 546.4 562.8

Ⅰ. Capital 52.0 54.1 64.5

Ⅱ. Additional Paid-in Capital 199.5 294.8 884.4

Ⅲ. Earned surplus 96.9 178.3 226.5

Ⅳ. Elements of other shareholder's equity

-9.9 240.8 196.8

V. Non-controlling interests -13.2 -19.4 -17.9

Total stockholders’ equity 325.3 748.5 1,354.3

SUBJECT 2014 2015 2016

Ⅰ. revenue 650.8 720.9 845.0

Domestic 224.8 218.5 256.3

Export 426.0 502.4 588.6

Ⅱ. 0perating Income 27.9 52.7 66.7

Ⅲ. Pre-tax Income 10.5 58.3 75.5

Ⅳ. Net Income 8.7 52.6 53.0

SUBJECT 2014 2015 2016

Operating Cash flow 48.4 77.7 55.7

50

Statement of Financial Position Statement of Comprehensive Income

Statement of Cash Flow

FINANCIAL STATEMENTS (K-IFRS, IN KRW 0.1B, NON-CONSOLIDATED)

SUBJECT 2014 2015 2016

Ⅰ. Current assets 310.1 556.0 1,132.4

Ⅱ. Noncurrent assets 595.3 840.4 952.1

Intangible assets other than goodwill

213.9 292.8 309.4

Total Assets 905.4 1,396.4 2,084.5

Ⅰ. Current Liabilities 266.1 296.5 310.2

Ⅱ. Noncurrent Liabilities 152.8 177.7 171.0

Total liabilities 418.9 474.2 481.2

Ⅰ. Capital 52.0 54.1 64.5

Ⅱ. Additional Paid-in Capital 199.5 294.8 884.4

Ⅲ. Earned surplus 248.7 331.6 455.5

Ⅳ. Elements of other shareholder's equity

-13.7 241.8 198.9

Total stockholders’ equity 486.5 922.3 1,603.3

SUBJECT 2014 2015 2016

Ⅰ. revenue 638.1 710.1 810.3

Ⅱ. 0perating Income 61.7 79.8 143.2

Ⅲ. Pre-tax Income 53.3 86.8 156.0

Ⅳ. Net Income 52.0 80.9 132.0

SUBJECT 2014 2015 2016

Operating Cash flow 67.8 83.7 66.9

51

Statement of Financial Position Statement of Comprehensive Income

Statement of Cash Flow

CONTACT US 219 Sowonro, Deogyang-gu, Goyang-si, Gyeonggi-do, Republic of Korea

kmmoon@lutronic.com / +82.70.4714.6024

52